Literature DB >> 19922807

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.

Pere Barba1, Jose Luis Piñana, Rodrigo Martino, David Valcárcel, Alex Amorós, Anna Sureda, Javier Briones, Julio Delgado, Salut Brunet, Jorge Sierra.   

Abstract

Patient comorbidities are being increasingly analyzed as predictors for outcome after hematopoietic stem cell transplantation (HSCT), especially in allogeneic HSCT (Allo-HSCT). Researchers from Seattle have recently developed several pretransplant scoring systems (hematopoietic cell transplantation comorbidity index [HCT-CI] and the Pretransplantation Assessment of Mortality (PAM) model) from large sets of HSCT recipients with the aim of improving non-transplant models, mainly the Charlson Comorbidity Index (CCI). The validation of these comorbidity indexes in other institutions and in different disease and conditioning-related settings is of interest to determine whether these models are potentially applicable in clinical practice and in research settings. We performed a retrospective study in our institution including 194 consecutive reduced-intensity conditioning (RIC) AlloHSCT (allo-RIC) recipients to compare the predictive value of the PAM score, CCI, the original HCT-CI, and the flexible HCT-CI using a different risk group stratification. The median patient pretransplant scores for the HCT-CI, PAM, and CCI were 3.5, 22, and 0, respectively. The flexible HCT-CI risk-scoring system (restratified as: low risk [LR] 0-3 points, intermediate risk [IR] 4-5 points, and high risk [HR] >5 points) was the best predictor for non-relapse mortality (NRM). The 100-day and 2-year NRM incidence in these risk categories was 4% (95% confidence interval C.I. 2%-11%), 16% (95% C.I. 9%-31%), and 29% (95% C.I. 19%-45%), respectively (P < .001), and 19% (95% C.I. 12%-28%), 33% (95% C.I. 22%-49%), and 40% (95% C.I. 28%-56%), respectively (P=.01). However, we found no predictive value for NRM using neither the original HCT-CI nor the PAM or CCI models. The better predictive capacity for NRM of the flexible HCT-CI than PAM and CCI was confirmed with the c-statistics (c-statistics of 0.672, 0.634, and 0.595, respectively). Regarding the 2-year overall survival (OS), the flexible HCT-CI score categories were also associated with the highest predictive HR. In conclusion, our single-center study suggests that the flexible HCT-CI is a good predictor of 2-year NRM and survival after an allo-RIC. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19922807     DOI: 10.1016/j.bbmt.2009.11.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  18 in total

Review 1.  Who is fit for allogeneic transplantation?

Authors:  H Joachim Deeg; Brenda M Sandmaier
Journal:  Blood       Date:  2010-08-11       Impact factor: 22.113

2.  Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Authors:  Mahmoud Elsawy; Barry E Storer; Filippo Milano; Brenda M Sandmaier; Colleen Delaney; Rachel B Salit; Ahmed H Rashad; Ann E Woolfrey; Frederick R Appelbaum; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

Authors:  Roni Shouval; Joshua A Fein; Aniela Shouval; Ivetta Danylesko; Noga Shem-Tov; Maya Zlotnik; Ronit Yerushalmi; Avichai Shimoni; Arnon Nagler
Journal:  Blood Adv       Date:  2019-06-25

4.  Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Authors:  Brandon K C Au; Ted A Gooley; Philippe Armand; Min Fang; David K Madtes; Mohamed L Sorror; Michael J Boeckh; Christopher J Gibson; Hans Joachim Deeg; Rainer Storb; Frederick R Appelbaum; Jason W Chien; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-31       Impact factor: 5.742

Review 5.  Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.

Authors:  M Elsawy; M L Sorror
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

6.  Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation.

Authors:  P Barba; R Martino; G Orti; A Esquirol; S Perez-Hoyos; J Sierra; D Valcárcel
Journal:  Bone Marrow Transplant       Date:  2015-06-22       Impact factor: 5.483

7.  Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.

Authors:  Mahmoud ElSawy; Barry E Storer; Michael A Pulsipher; Richard T Maziarz; Smita Bhatia; Michael B Maris; Karen L Syrjala; Paul J Martin; David G Maloney; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Br J Haematol       Date:  2015-05-05       Impact factor: 6.998

Review 8.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

9.  How I assess comorbidities before hematopoietic cell transplantation.

Authors:  Mohamed L Sorror
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

Review 10.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.